AlphaFold predicted structure
SLC30A5 · Q8TAD4

Mean pLDDT
76.3/ 100
Confident
765 residues
Confidence breakdown
- Very high(≥ 90)28%
- Confident(70–90)44%
- Low(50–70)12%
- Very low(< 50)15%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
solute carrier family 30 member 5
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Fetal anomalies
BIALLELIC, autosomal or pseudoautosomalFetal hydrops
BIALLELIC, autosomal or pseudoautosomalPaediatric or syndromic cardiomyopathy
BIALLELIC, autosomal or pseudoautosomalhydrops fetalis
hypertrophic cardiomyopathy
Concentric hypertrophic cardiomyopathy
Noncompaction cardiomyopathy
Abnormality of the skeletal system
Sensorineural hearing impairment
hypertensive disorder
pathological myopia
ovarian dysfunction
skin disorder
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Proton-coupled zinc antiporter SLC30A5
Together with SLC30A6 forms a functional proton-coupled zinc ion antiporter mediating zinc entry into the lumen of organelles along the secretory pathway (PubMed:11904301, PubMed:15525635, PubMed:15994300, PubMed:19366695, PubMed:22529353). By contributing to zinc ion homeostasis within the early secretory pathway, regulates the activation and folding of enzymes like alkaline phosphatases and enzymes involved in phosphatidylinositol glycan anchor biosynthesis (PubMed:15525635, PubMed:15994300, PubMed:16636052, PubMed:35525268). Through the transport of zinc into secretory granules of pancreatic beta-cells, plays an important role in the storage and secretion of insulin (PubMed:11904301)
SLC30A5 · Q8TAD4

Mean pLDDT
76.3/ 100
Confident
765 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0